FDA approvals, label changes and boxed warning updates for hormone therapy and non-hormonal menopause drugs, guideline changes from major societies, generic launches and price changes, insurer and Medicare formulary changes, telehealth menopause clinic actions, workplace menopause policy adoptions, and major study results with clinical implications, with the drug or guideline first.